Efficacité et sécurité du traitement par Ixekizumab chez les patients atteints de spondylarthrite axiale : résultats à deux ans de l'étude COAST
RMD Open. 2022 doi: 10.1136/rmdopen-2021-002165
This study highlighted improvements in disease activity, function and quality of life were achieved early on into treatment and were sustained through 116 weeks of IXE therapy for patients with r-axSpA and nr-axSpA. In this study investigators aimed to report the long-term efficacy and safety results for patients treated with ixekizumab for up to 116 weeks.